Browse by category

The initial results of a study assessing the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence, has reported that after 12 months, the average total body weight loss was 23%, and lean body mass as a percentage of total body weight increased by 14% from 62% to 70%. “These results provide additional data that a combination approach with the Allurion Smart Capsule and GLP-1 medications has several advantages,” said

Allurion Technologies has revealed a strategic direction with an increasing focus on low-dose GLP-1 combination therapy, muscle mass...

Allurion Technologies is relaunching the Allurion Balloon in France after the Agence nationale de sécurité du médicament et des produits...

Allurion Technologies has launched AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss...

Allurion Technologies has announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an...

Allurion Technologies has revealed data from a study of 121 patients across 11 obesity centres treated with two consecutive, four-month...

Allurion Technologies has announced that the Somerset NHS Foundation Trust is the first NHS trust in the UK - and the first non-private...

Allurion Technologies has completed patient enrolment in its AUDACITY trial, a randomised, pivotal controlled trial designed to support...

Allurion Technologies has launched Coach Iris, a new generative AI-powered health coach designed to enhance outcomes within the Allurion...

Allurion Technologies and Compute Health Acquisition have entered into a definitive business combination agreement that will result in...